No. |
Drug (Description in trials) |
DrugBank |
KEGG DRUG * |
KEGG GENES * [Number of genes] |
KEGG PATHWAY [Number of pathways] |
Disease ID * [Number of diseases] |
1 |
Active topical ns2 1% dermatologic cream |
- |
- |
- |
- |
[1] 160 |
2 |
Adalimumab |
Adalimumab |
D02597 |
[1] TNF |
[61] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
[15] 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
3 |
Adx-102 1% topical dermal cream (reproxalap) |
- |
- |
- |
- |
[1] 160 |
4 |
Apply veregen ® 10 % on a randomized area and the moisturizing cream of the other side |
- |
- |
- |
- |
[1] 160 |
5 |
Atorvastatin |
Atorvastatin |
D00258, D00887, D07474 |
[1] HMGCR |
[4] AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
[17] 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 160, 222, 225, 265, 271, 299 |
6 |
Bezafibrate |
Bezafibrate |
D01366 |
[1] PPARA |
[7] Adipocytokine signaling pathway, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease (NAFLD), PPAR signaling pathway, cAMP signaling pathway |
[5] 20, 93, 94, 160, 316 |
7 |
Bezalip retard |
- |
- |
- |
- |
[1] 160 |
8 |
Bpr277 |
- |
- |
- |
- |
[1] 160 |
9 |
Cholesterol |
Cholesterol |
D00040 |
- |
- |
[7] 19, 90, 160, 259, 261, 301, 310 |
10 |
Cnt-02 |
- |
- |
- |
- |
[1] 160 |
11 |
Epithelial sheet generated from transduced autologous keratinocytes using pccl-invo-sp |
- |
- |
- |
- |
[1] 160 |
12 |
Fibrate treatment |
- |
- |
- |
- |
[1] 160 |
13 |
Hematopoetic stem cell transplantation |
- |
- |
- |
- |
[5] 19, 65, 120, 160, 326 |
14 |
Isotretinoin |
Isotretinoin |
D00348 |
[2] RARA, RARB |
[8] Acute myeloid leukemia, Estrogen signaling pathway, Gastric cancer, Non-small cell lung cancer, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Transcriptional misregulation in cancer |
[4] 36, 39, 159, 160 |
15 |
Kb105 |
- |
- |
- |
- |
[1] 160 |
16 |
Lipoxygenase inhibitor |
- |
- |
- |
- |
[1] 160 |
17 |
Lovastatin |
Lovastatin |
D00359 |
[1] HMGCR |
[4] AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
[10] 6, 34, 46, 79, 156, 160, 195, 206, 263, 310 |
18 |
Monolaurin cream |
- |
- |
- |
- |
[1] 160 |
19 |
None |
- |
- |
- |
- |
[8] 46, 78, 84, 96, 160, 161, 171, 299 |
20 |
Oxiconazole |
Oxiconazole |
D00885, D08313 |
- |
- |
[1] 160 |
21 |
Pat-001, 0.1% |
- |
- |
- |
- |
[1] 160 |
22 |
Pat-001, 0.2% |
- |
- |
- |
- |
[1] 160 |
23 |
Pimecrolimus |
Pimecrolimus |
D05480 |
[5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
[30] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
[1] 160 |
24 |
Pimecrolimus 1% cream |
Pimecrolimus |
D05480 |
[5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
[30] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
[1] 160 |
25 |
Rvg 18388 |
- |
- |
- |
- |
[1] 160 |
26 |
Secukinumab |
Secukinumab |
D09967 |
[1] IL17A |
[5] Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease (IBD), Rheumatoid arthritis, Th17 cell differentiation |
[7] 13, 37, 41, 46, 160, 269, 271 |
27 |
Vehicle |
- |
- |
- |
- |
[4] 6, 36, 160, 192 |
28 |
Vehicle of adx-102 topical dermal cream |
- |
- |
- |
- |
[1] 160 |
29 |
Veregen(r) |
- |
- |
- |
- |
[1] 160 |
30 |
Zileuton |
Zileuton |
D00414 |
[1] ALOX5 |
[6] Arachidonic acid metabolism, Fc epsilon RI signaling pathway, Metabolic pathways, Ovarian steroidogenesis, Serotonergic synapse, Toxoplasmosis |
[3] 85, 160, 164 |
31 |
Zyflo cr |
Zileuton |
D00414 |
[1] ALOX5 |
[6] Arachidonic acid metabolism, Fc epsilon RI signaling pathway, Metabolic pathways, Ovarian steroidogenesis, Serotonergic synapse, Toxoplasmosis |
[1] 160 |